BLT looks like it has fixed the gremlins in it's clinical trial. Logic says it should rerate. Brokers have it worth $3-$4. But who knows. NXR was the Giz's parting gift. May it continue to give.
Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat
